Key facts
- Notable investors include Nucleus Fund.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Corventum
- ·The full record, as it builds
Funding rounds
No funding rounds for Corventum are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Corventum
Developer of a heart-protecting drug designed to prevent cardiac damage caused by cancer treatments. The company's platform advances a small molecule compound that shields the heart from the toxic side effects of chemotherapy, enabling cancer patients to complete their full course of treatment safely without life-threatening heart complications.
- Sector
- Healthcare
- HQ
- Boulder, CO, United States
- Founded
- 2023
- Employees
- 3
- Website
- corventum.com/
- Ownership
- Privately Held (backing)
Corventum doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Corventum shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Corventum in its N-PORT filings yet. We sweep new filings monthly.